A high-purity nucleoside analog engineered to inhibit viral replication at the cellular level. This treatment protocol has established the global benchmark for FIP clinical recovery due to its superior safety profile and predictable pharmacokinetics.
Dry Form
- Chronic Lethargy
- Recurrent Fever
- Visible Jaundice
- Muscle Wasting
Wet Form
- Abdominal Distension
- Fluid in Chest
- Difficulty Breathing
Ocular Form
- Uveitis
- Cloudy Vision
- Corneal Thickening
Neurological Form
- Loss of Equilibrium
- Persistent Head Tilt
- Seizures


